ClinicalTrials.gg
CompletedNCT05166161Updated Sep 9, 2026

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

A Phase 3 interventional study of PTC923 in Phenylketonuria, sponsored by PTC Therapeutics. Completed at 46 sites in 19 countries. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by PTC Therapeutics · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
247
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Enrollment
4th of 63
247 · median 33
Started
2022
with 5 others
Phase 3
16 of 93
3 open now
Registered
70th of 93
by date
Lead sponsor
4 of 93
PTC Therapeutics

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 4th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2022, is one of 16 in phase 3, and was the 70th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.

Read the detailed description

Eligible participants are:

Feeder participants: those who have completed a Phase 3 PTC Therapeutics (PTC) sponsored feeder study.

Non-feeder controlled participants: those who have not completed a feeder study and have blood Phe levels \<360 μmol/L at study entry.

Non-feeder uncontrolled participants: those who have not completed a feeder study and have blood Phe levels ≥360 μmol/L at study entry.

03

Conditions studied

  • Phenylketonuria

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PKU with hyperphenylalaninemia (HPA) documented by past medical history of at least 2 blood Phe measurements ≥600 μmol/L.
  • Women of must have a negative pregnancy test at screening and agree to abstinence or the use of at least one highly effective form of for the duration of the study, and for up to 90 days after the last dose of the study drug.
  • Males who are sexually active with women of childbearing potential who have not had a vasectomy must agree to use a barrier method of birth control during the study and for up to 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period.
  • Willing to continue current diet unchanged while participating in the study (unless specifically instructed to change diet during the study by the investigator).

Exclusion criteria

Exclusion Criteria:

  • Inability to tolerate oral medication.
  • A female who is pregnant or breastfeeding, or considering pregnancy.
  • Serious neuropsychiatric illness (for example, major depression) not currently under medical control, that in the opinion of the investigator or PTC, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant.
  • Past medical history and/or evidence of renal impairment and/or condition including moderate/severe renal insufficiency ( [GFR] \<60 milliliters [mL]/minute [min] min as estimated most recently during qualifying participation in a feeder study) and/or under care of a nephrologist.
  • Any other condition that in the opinion of the investigator or PTC, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant.
  • Requirement for concomitant treatment with any drug known to inhibit folate synthesis (for example, methotrexate).
  • Concomitant treatment with tetrahydrobiopterin (BH4) supplementation (for example, sapropterin dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ).

Additional criteria for non-feeder participants who did not participate in a feeder study:

  • Gastrointestinal disease (such as irritable bowel syndrome, inflammatory bowel disease, chronic gastritis, and peptic ulcer disease, etc) that could affect the absorption of study drug.
  • History of gastric surgery, including Roux-en-Y gastric bypass surgery or an antrectomy with vagotomy, or gastrectomy.
  • History of allergies or adverse reactions to synthetic BH4 or sepiapterin.
  • Any laboratory abnormality as determined by the investigator.
  • Any abnormal physical examination and/or laboratory findings indicative of signs or symptoms of renal disease, including calculated GFR \<60 milliliters (mL)/minute/1.73 square meter (m\^2).

Confirmed diagnosis of a primary BH4 deficiency as evidenced by biallelic pathogenic mutations in 6-pyruvoyltetrahydropterin synthase, recessive GTP cyclohydrolase I, sepiapterin reductase, quinoid dihydropteridine reductase, or pterin-4-alphacarbinolamine dehydratase genes.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    PTC923

    Participants will receive PTC923 7.5 mg/kg (participants 0 to \<6 months of age), 15 mg/kg (participants 6 to \<12 months of age), 30 mg/kg (participants 12 months to \<2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for a minimum of 12 months or until participant experiences lack of efficacy, adverse events (AEs) that lead to discontinuation, withdraws from treatment, or PTC923 is authorized and commercially available in the specific country.

    Drug: PTC923

Interventions

  • DrugSepiapterinStudies of SepiapterinSepiapterin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PTC923 powder for oral use will be suspended in water or apple juice prior to administration.

    Also known as: Sepiapterin, Sephience

06

What researchers measure

Primary outcomes

  1. Number of Treatment-Emergent Adverse Events (TEAEs)

    A TEAE is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease in a study participant who is administered study drug in this study

    Time frame: Baseline up to end of study (up to 4 years)

  2. Change From Baseline in Dietary Phe/Protein Consumption at Week 26, Measured During Phe Tolerance Assessment Period

    Phe tolerance is defined as the total amount of dietary Phe (milligrams \[mg\]/kilogram \[kg\] per day) ingested while maintaining blood Phe levels within the range of 40 to 360 micromoles (μmol)/liter (L) (defined as ≥40 to \<360 μmol/L).

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in Quality of Life (QOL) Using Phenylketonuria-Quality of Life (PKU-QOL) Questionnaire at Months 8, 14, 20, 26, 32, and 38

    QOL using PKU-QOL questionnaire will be assessed in the subset of participants who are able to complete the PKU-QOL (that is, participants whose primary language is English \[British or American\], Turkish, Dutch, German, Spanish, Italian, Portuguese, or French) (ages 6 to 8 years Parent PKU-QOL; ages 9 to 11 years Child PKU-QOL; ages 12 to 17 years Adolescent PKU-QOL; ages ≥18 years Adult PKU-QOL).

    Time frame: Baseline, Months 8, 14, 20, 26, 32, and 38

  2. Change From Baseline in QOL Using the European Quality of Life - 5 Dimensions (EQ-5D) at Months 8, 14, 20, 26, 32, and 38

    QOL will be assessed using the EQ-5D (EQ-5D-Y Proxy Version 1 \[3 to 7 years\]; EQ-5D-Y \[8 to 15 years\]; EQ-5D-5L (\[≥16 years\]).

    Time frame: Baseline, Months 8, 14, 20, 26, 32, and 38

  3. Palatability of PTC923

    For participants \<5 years of age, palatability will be indirectly assessed by the parent(s)/caregiver(s) of participants using the following: On the basis of the reaction/facial expression of your child, do you think that the medication is (pleasant, not sure, unpleasant)?

    Time frame: Month 1 Day 1

  4. Acceptability/Ease of Administration of PTC923

    For all participants \<12 years of age, parent(s)/caregiver(s) will rate the acceptability/ease of administration, with the following question: Do you sometimes have problems in giving the medication to your child because he/she refuses to take it or throws it up? (Yes/No).

    Time frame: Month 1 Day 1

  5. Taste/Flavor Assessment Using a Facial Hedonic Scale

    For participants ≥5 to \<18 years of age who are able to comply with the instructions, the participant will rate the taste/flavor using a facial hedonic scale (5=really good; 4=good; 3=not sure; 2=bad; 1=really bad).

    Time frame: Month 1 Day 1

  6. Plasma Sepiapterin Concentration

    Time frame: Month 1 Day 1 up to Month 11 Day 1

  7. Plasma BH4 Concentration

    Time frame: Month 1 Day 1 up to Month 11 Day 1

07

Study locations

46 sites
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism
    Gainesville, Florida 32610, United States
  • Indiana University School of Medicine Department of Medical and Molecular Genetics
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Icahn School of Medicine at Mount Sinai (ISMMS)
    New York, New York 10009, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • University of Utah
    Salt Lake City, Utah 84108, United States
  • The Queensland Children's Hospital
    South Brisbane, Brisbane, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • PARC Clinical Research
    Adelaide, South Australia SA 5000, Australia
  • Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Hospital de clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Metabolics and Genetics in Calgary (MAGIC) Clinic, Ltd.
    Calgary, Alberta T2E 7Z4, Canada
  • McMaster Children's Hospital Hamilton Health Sciences
    Hamilton, Ontario L8N 3Z5, Canada
  • The Hospital for Sick Children University of Toronto Adult Clinic: The Fred A Litwin Family Centre in Genetic Medicine University Health Network & Mt. Sinai Hospital
    Toronto, Ontario M5G 1X8, Canada
  • Fakultní nemocnice Královské Vinohrady Klinika dětí a dorostu Ambulance pro léčbu PKU a HPA
    Prague, 100 34, Czechia
  • Copenhagen University Hospital, Rigshospitalet
    Copenhagen, DK-2100, Denmark
  • Hôpital Necker-Enfants Malades - Centre de Référence des Maladies Héréditaires du Métabolisme
    Paris, 75015, France
  • Medical Genetics and Laboratory Diagnostics Center
    Tbilisi, 0159, Georgia
  • University Children's Hospital Hamburg Eppendorf (Kinder-UKE) Klinik für Kinder- und Jugendmedizin (Kinder-UKE)
    Hamburg, 20246, Germany
  • Universitätsklinikum Heidelberg / Zentrum für Kinder- und Jugendmedizin / Sektion für Neuropädiatrie & Stoffwechselmedizin
    Heidelberg, 69120, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Azienda Ospedaliera-Universita Padova
    Padua, Veneto 35129, Italy
  • Department of Human Neuroscience, Child and Adolescent Neuropsychiatry, Policlinico Umberto I
    Rome, 00185, Italy
  • PTC Clinical Site 1
    Multiple Locations, Japan
  • PTC Clinical Site 2
    Multiple Locations, Japan
  • PTC Clinical Site 3
    Multiple Locations, Japan
  • PanAmerican Clinical Research
    Guadalajara, Jalisco 44670, Mexico
  • UMCG Beatrix Children's Hospital
    Groningen, 9713 GZ, Netherlands
  • Pomorski Uniwersytet Medyczny w Szczecinie Centrum Wsparcia Badań Klinicznych
    Szczecin, 71-252, Poland
  • CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria,
    Lisbon, Estremadura 1649-035, Portugal
  • CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria
    Lisbon, Estremadura 1649-035, Portugal
  • Centro Hospitalar Universitário Do Porto, Epe
    Porto, 4099-001, Portugal
  • Univerzitetni klinicni center Ljubljana
    Ljubljana, 1000, Slovenia
  • Hospital Sant Joan de Déu
    Barcelona, Esplugues de Llobregat 08950, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
  • Hacettepe University Medical Faculty
    Altındağ, Ankara 06230, Turkey (Türkiye)
  • Gazi Üniversitesi Tıp Fakültesi
    Yenimahalle, Ankara 06500, Turkey (Türkiye)
  • İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi
    Fatih, Istanbul 34098, Turkey (Türkiye)
  • Ege University Faculty of Medicine Children Hospital
    Bornova, İzmir 35100, Turkey (Türkiye)
  • Çukurova Üniversitesi Tıp Fakültesi Balcalı Hastanesi
    Adana, 01330, Turkey (Türkiye)
  • Birmingham Children's Hospital NHS Foundation Trust
    Birmingham, B4 6NH, United Kingdom
  • UNIVERSITY HOSPITALS BIRMINGHAM NHS Foundation Trust
    Birmingham, United Kingdom
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
08

References and documents

Publications

  • van Spronsen F, Peters H, Margvelashvili L, Agladze D, Schwartz IVD, Gizewska M, Hamazaki T, Guilder L, MacDonald A, Vijay S, Inwood A, Minami M, Fjellbirkeland O, Lund A, Lah M, Thomas JA, Longo N, Kiykim E, Ishige M, Burlina A, Belanger-Quintana A, Rutsch F, Opladen T, Mungan H, Ezgu F, Bratkovic D, Chakrapani A, Ito T, Guimas A, Zori R, Tchan M, Sacharow S, Oliveira A, Janeiro P, Guerra IC, Plana JC, Yildiz Y, Canda E, Khan A, Vockley J, Breilyn MS, Manti F, Larkin A, Hughes C, Liu E, Gao L, Ingalls K, Smith N, Muntau AC. Effect of long-term sepiapterin treatment on dietary phenylalanine tolerance in patients with phenylketonuria: Interim results from the phase 3 APHENITY Extension Study. Genet Med. 2026 Apr;28(4):101683. doi: 10.1016/j.gim.2026.101683. Epub 2026 Jan 12. PubMed 41537382 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jul 2026, 53 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Dec 21, 2021
StartActual
Feb 14, 2022
Primary completionActual
Jul 21, 2026
CompletionActual
Jul 21, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05166161
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Dec 21, 2021
Start date
Feb 14, 2022
Primary completion
Jul 21, 2026
Completion
Jul 21, 2026
Last update
Sep 9, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sepiapterin

Start the discussion